Schlagwort: Gesundheit / Medizin

国际制药专业知识助力可持续发展 AOP Health迎来了国际化管理人才Jean-Michel Quinot，他于2025年4月担任首席运营官（COO），为公司在战略转型期注入了丰富的经验。未来五年内，公司将专注于雄心勃勃的扩展目标，包括进入美国市场，并致力于成为全球领先的制药企业。这一人事变动彰显了AOP Health作为欧洲稀有疾病和重症医学专家，继续追求国际增长的决心。 作为首席运营官，同时也是公司执行委员会的一员，Quinot将重点放在提升运营卓越性、统一核心流程以及建立清晰沟通结构上。他强调：“我们需要减少复杂性，同时激励员工。因此，明确愿景和尊重领导是必不可少的。” 以态度引领 Quinot认为，人是企业运作中的核心，因此他视自己为团队发展的推动者：“我希望确保我的团队在专业技能、个人成长和责任感方面不断进步。” 为了实现这一目标，他认为优秀领导所需的是团队精神、清晰度以及前瞻性的思维。在一个从研究密集型中小企业向全球供应商转型的公司中，方向感尤为重要：“每个人都应该知道我们的目标是什么。” 此外，他还强调，通过自己的工作为患者创造价值至关重要。他表示：“AOP Health致力于为稀有疾病患者及重症医学领域提供解决方案，以满足他们未被满足的医疗需求。在欧洲，我们已经走上了良好的发展道路，我希望能够将这一成就推广到全球范围。” 全球化经验 Jean-Michel Quinot拥有丰富的国际职业经历，在欧洲、非洲、亚洲和北美等地都有过任职经历。他曾担任百时美施贵宝公司的总经理，以及Nordic Pharma公司的首席执行官，这些经历对他的职业生涯影响深远。此外，他还在瑞士创办并成功扩展了一家名为Amring International 的仿制药公司，这些经验将在他加入AOP Health后发挥重要作用。 "我本质上是一名企业家。我受到新想法、多元文化及对医疗进步做出贡献这三者驱动。" Quinot说道。最近，他与初创公司的合作展示了他的创新精神，最终使他被AOP ...

%3Cp%3E%20%E5%9B%BD%E9%99%85%E5%88%B6%E8%8D%AF%E4%B8%93%E4%B8%9A%E7%9F%A5%E8%AF%86%E5%8A%A9%E5%8A%9B%E5%8F%AF%E6%8C%81%E7%BB%AD%E5%8F%91%E5%B1%95%20%3C/p%3E%0A%3Cp%3E%20%3Cb%3EAOP%20Health%E6%96%B0%E4%BB%BB%E9%A6%96%E5%B8%AD%E8%BF%90%E8%90%A5%E5%AE%98Jean-Michel%20Quinot%E7%9A%84%E5%8A%A0%E5%85%A5%EF%BC%8C%E4%B8%BA%E5%85%A8%E7%90%83%E4%BC%81%E4%B8%9A%E7%AE%A1%E7%90%86%E6%B3%A8%E5%85%A5%E4%BA%86%E4%B8%B0%E5%AF%8C%E7%9A%84%E5%9B%BD%E9%99%85%E7%BB%8F%E9%AA%8C%E3%80%82%E8%BF%99%E4%BD%8D%E5%87%BA%E7%94%9F%E4%BA%8E%E6%B3%95%E5%9B%BD%E7%9A%84%E9%AB%98%E7%AE%A1%E4%BA%8E2025%E5%B9%B44%E6%9C%88%E6%8B%85%E4%BB%BBCOO%EF%BC%8C%E6%AD%A3%E5%80%BC%E5%85%AC%E5%8F%B8%E5%9C%A8%E6%88%98%E7%95%A5%E8%BD%AC%E5%9E%8B%E6%9C%9F%EF%BC%8C%E4%BB%96%E5%B0%86%E5%88%A9%E7%94%A8%E8%87%AA%E5%B7%B1%E5%A4%9A%E5%B9%B4%E7%9A%84%E8%A1%8C%E4%B8%9A%E4%B8%93%E9%95%BF%EF%BC%8C%E6%8E%A8%E5%8A%A8%E5%88%B02030%E5%B9%B4%E7%9A%84%E9%9B%84%E5%BF%83%E5%8B%83%E5%8B%83%E6%89%A9%E5%B1%95%E8%AE%A1%E5%88%92%EF%BC%8C%E5%8C%85%E6%8B%AC%E8%BF%9B%E5%85%A5%E7%BE%8E%E5%9B%BD%E5%B8%82%E5%9C%BA%EF%BC%8C%E5%B9%B6%E8%87%B4%E5%8A%9B%E4%BA%8E%E6%89%93%E9%80%A0%E4%B8%80%E4%B8%AA%E5%85%A8%E7%90%83%E6%80%A7%E7%9A%84%E5%88%B6%E8%8D%AF%E4%BC%81%E4%B8%9A%E3%80%82%E9%80%9A%E8%BF%87%E8%BF%99%E4%B8%80%E4%BA%BA%E4%BA%8B%E5%8F%98%E5%8A%A8%EF%BC%8CAOP%20Health%E9%87%8D%E7%94%B3%E4%BA%86%E5%85%B6%E4%BD%9C%E4%B8%BA%E6%AC%A7%E6%B4%B2%E7%A8%80%E6%9C%89%E7%96%BE%E7%97%85%E5%92%8C%E9%87%8D%E7%97%87%E5%8C%BB%E5%AD%A6%E4%B8%93%E5%AE%B6%EF%BC%8C%E5%9C%A8%E5%9B%BD%E9%99%85%E4%B8%8A%E8%BF%9B%E4%B8%80%E6%AD%A5%E5%8F%91%E5%B1%95%E7%9A%84%E5%86%B3%E5%BF%83%E3%80%82%3C/b%3E%20%3C/p%3E%0A%3Cp%3E%20%E4%BD%9C%E4%B8%BA%E9%A6%96%E5%B8%AD%E8%BF%90%E8%90%A5%E5%AE%98%EF%BC%8C%E5%90%8C%E6%97%B6%E4%B9%9F%E6%98%AF%E5%85%AC%E5%8F%B8%E6%89%A7%E8%A1%8C%E5%A7%94%E5%91%98%E4%BC%9A%E7%9A%84%E4%B8%80%E5%91%98%EF%BC%8CQuinot%E5%B0%86%E9%87%8D%E7%82%B9%E6%94%BE%E5%9C%A8%E6%8F%90%E5%8D%87%E8%BF%90%E8%90%A5%E5%8D%93%E8%B6%8A%E6%80%A7%E3%80%81%E7%BB%9F%E4%B8%80%E6%A0%B8%E5%BF%83%E6%B5%81%E7%A8%8B%E4%BB%A5%E5%8F%8A%E5%BB%BA%E7%AB%8B%E6%B8%85%E6%99%B0%E6%B2%9F%E9%80%9A%E7%BB%93%E6%9E%84%E4%B8%8A%E3%80%82%E4%BB%96%E5%BC%BA%E8%B0%83%EF%BC%9A%E2%80%9C%E6%88%91%E4%BB%AC%E9%9C%80%E8%A6%81%E5%87%8F%E5%B0%91%E5%A4%8D%E6%9D%82%E6%80%A7%EF%BC%8C%E5%90%8C%E6%97%B6%E6%BF%80%E5%8A%B1%E5%91%98%E5%B7%A5%E3%80%82%E6%98%8E%E7%A1%AE%E7%9A%84%E6%84%BF%E6%99%AF%E5%92%8C%E5%B0%8A%E9%87%8D%E9%A2%86%E5%AF%BC%E6%98%AF%E4%B8%8D%E5%8F%AF%E6%88%96%E7%BC%BA%E7%9A%84%E3%80%82%E2%80%9D%20%3C/p%3E%0A%3Cp%3E%20%3Cb%3E%E4%BB%A5%E4%BB%B7%E5%80%BC%E8%A7%82%E5%BC%95%E9%A2%86%E7%AE%A1%E7%90%86%3C/b%3E%20%3C/p%3E%0A%3Cp%3E%20Quinot%E8%AE%A4%E4%B8%BA%EF%BC%8C%E4%BA%BA%E6%98%AF%E5%95%86%E4%B8%9A%E6%B4%BB%E5%8A%A8%E4%B8%AD%E7%9A%84%E6%A0%B8%E5%BF%83%EF%BC%8C%E5%9B%A0%E6%AD%A4%E4%BB%96%E4%B9%9F%E8%A7%86%E8%87%AA%E5%B7%B1%E4%B8%BA%E5%9B%A2%E9%98%9F%E5%8F%91%E5%B1%95%E7%9A%84%E6%8E%A8%E5%8A%A8%E8%80%85%EF%BC%9A%E2%80%9C%E6%88%91%E5%B8%8C%E6%9C%9B%E7%A1%AE%E4%BF%9D%E6%88%91%E7%9A%84%E5%9B%A2%E9%98%9F%E5%9C%A8%E4%B8%93%E4%B8%9A%E3%80%81%E4%B8%AA%E4%BA%BA%E5%8F%8A%E8%B4%A3%E4%BB%BB%E6%84%9F%E6%96%B9%E9%9D%A2%E4%B8%8D%E6%96%AD%E6%88%90%E9%95%BF%E3%80%82%E2%80%9D%20%3C/p%3E%0A%3Cp%3E%20%E4%B8%BA%E5%AE%9E%E7%8E%B0%E8%BF%99%E4%B8%80%E7%9B%AE%E6%A0%87%EF%BC%8C%E4%BB%96%E8%AE%A4%E4%B8%BA%E4%BC%98%E7%A7%80%E9%A2%86%E5%AF%BC%E9%9C%80%E5%85%B7%E5%A4%87%E5%9B%A2%E9%98%9F%E7%B2%BE%E7%A5%9E%E3%80%81%E6%B8%85%E6%99%B0%E5%BA%A6%E4%BB%A5%E5%8F%8A%E5%89%8D%E7%9E%BB%E6%80%A7%E7%9A%84%E6%80%9D%E7%BB%B4%E8%83%BD%E5%8A%9B%E3%80%82%E5%9C%A8%E4%B8%80%E4%B8%AA%E4%BB%8E%E7%A0%94%E7%A9%B6%E5%AF%86%E9%9B%86%E5%9E%8B%E4%B8%AD%E5%B0%8F%E4%BC%81%E4%B8%9A%E5%90%91%E5%85%A8%E7%90%83%E4%BE%9B%E5%BA%94%E5%95%86%E8%BD%AC%E5%9E%8B%E7%9A%84%E5%85%AC%E5%8F%B8%E4%B8%AD%EF%BC%8C%E6%96%B9%E5%90%91%E6%84%9F%E5%B0%A4%E4%B8%BA%E9%87%8D%E8%A6%81%EF%BC%9A%E2%80%9C%E6%AF%8F%E4%B8%AA%E4%BA%BA%E9%83%BD%E5%BA%94%E8%AF%A5%E7%9F%A5%E9%81%93%E6%88%91%E4%BB%AC%E7%9A%84%E7%9B%AE%E6%A0%87%E6%98%AF%E4%BB%80%E4%B9%88%E3%80%82%E2%80%9D%20%3C/p%3E%0A%3Cp%3E%20%E5%AF%B9%E4%BB%96%E8%80%8C%E8%A8%80%EF%BC%8C%E9%80%9A%E8%BF%87%E5%B7%A5%E4%BD%9C%E4%B8%BA%E6%82%A3%E8%80%85%E5%88%9B%E9%80%A0%E4%BB%B7%E5%80%BC%E5%90%8C%E6%A0%B7%E8%87%B3%E5%85%B3%E9%87%8D%E8%A6%81%E3%80%82%E4%BB%96%E8%A1%A8%E7%A4%BA%EF%BC%9A%E2%80%9CAOP%20Health%E8%87%B4%E5%8A%9B%E4%BA%8E%E4%B8%BA%E7%A8%80%E6%9C%89%E7%96%BE%E7%97%85%E6%82%A3%E8%80%85%E5%92%8C%E9%87%8D%E7%97%87%E5%8C%BB%E5%AD%A6%E9%A2%86%E5%9F%9F%E6%8F%90%E4%BE%9B%E6%9C%AA%E6%BB%A1%E8%B6%B3%E5%8C%BB%E7%96%97%E9%9C%80%E6%B1%82%E7%9A%84%E8%A7%A3%E5%86%B3%E6%96%B9%E6%A1%88%E3%80%82%E5%9C%A8%E6%AC%A7%E6%B4%B2%EF%BC%8C%E6%88%91%E4%BB%AC%E5%B7%B2%E7%BB%8F%E8%B5%B0%E4%B8%8A%E4%BA%86%E8%89%AF%E5%A5%BD%E7%9A%84%E5%8F%91%E5%B1%95%E9%81%93%E8%B7%AF%EF%BC%8C%E6%88%91%E5%B8%8C%E6%9C%9B%E8%83%BD%E5%B0%86%E8%BF%99%E4%B8%80%E7%9B%AE%E6%A0%87%E6%8E%A8%E5%B9%BF%E5%88%B0%E5%85%A8%E7%90%83%E8%8C%83%E5%9B%B4%E5%86%85%E3%80%82%E2%80%9D%20%3C/p%3E%0A%3Cp%3E%3Cb%20%3E%E5%9B%BD%E9%99%85%E5%8C%96%E8%83%8C%E6%99%AF%3C/b%3E%3C/p%3E%3Cp%20%3E%20Jean-Michel%20Quinot%E6%8B%A5%E6%9C%89%E4%B8%B0%E5%AF%8C%E5%A4%9A%E5%85%83%E5%8C%96%E7%9A%84%E8%81%8C%E4%B8%9A%E7%BB%8F%E5%8E%86%EF%BC%8C%E5%85%B6%E8%B6%B3%E8%BF%B9%E9%81%8D%E5%B8%83%E6%AC%A7%E6%B4%B2%E3%80%81%E9%9D%9E%E6%B4%B2%E3%80%81%E4%BA%9A%E6%B4%B2%E5%8F%8A%E5%8C%97%E7%BE%8E%E3%80%82%E4%BB%96%E6%9B%BE%E6%8B%85%E4%BB%BB%E7%99%BE%E6%97%B6%E7%BE%8E%E6%96%BD%E8%B4%B5%E5%AE%9D%EF%BC%88Bristol-Myers%20Squibb%EF%BC%89%E6%80%BB%E7%BB%8F%E7%90%86%EF%BC%8C%E4%BB%A5%E5%8F%8ANordic%20Pharma%E9%A6%96%E5%B8%AD%E6%89%A7%E8%A1%8C%E5%AE%98%EF%BC%8C%E8%BF%99%E4%BA%9B%E7%BB%8F%E5%8E%86%E5%AF%B9%E4%BB%96%E7%9A%84%E8%81%8C%E4%B8%9A%E7%94%9F%E6%B6%AF%E5%BD%B1%E5%93%8D%E6%B7%B1%E8%BF%9C%E3%80%82%E6%AD%A4%E5%A4%96%EF%BC%8C%E4%BB%96%E8%BF%98%E5%9C%A8%E7%91%9E%E5%A3%AB%E5%88%9B%E5%8A%9E%E5%B9%B6%E6%88%90%E5%8A%9F%E6%8B%93%E5%B1%95%E4%BA%86%E4%B8%80%E5%AE%B6%E5%90%8D%E4%B8%BAAmring%20International%20%E7%9A%84%E4%BB%BF%E5%88%B6%E8%8D%AF%E5%85%AC%E5%8F%B8%EF%BC%8C%E8%BF%99%E6%AE%B5%E7%BB%8F%E5%8E%86%E5%B0%86%E5%9C%A8%E4%BB%96%E6%9C%AA%E6%9D%A5%E5%9C%A8AOP%20Health%E7%9A%84%E5%8F%91%E5%B1%95%E4%B8%AD%E5%8F%91%E6%8C%A5%E9%87%8D%E8%A6%81%E4%BD%9C%E7%94%A8%E3%80%82%3C/p%3E%3Cp%20%3E%20%E2%80%9C%E6%88%91%E5%86%85%E5%BF%83%E6%B7%B1%E5%A4%84%E6%98%AF%E4%B8%80%E5%90%8D%E4%BC%81%E4%B8%9A%E5%AE%B6%E3%80%82%E6%88%91%E8%A2%AB%E6%96%B0%E6%83%B3%E6%B3%95%E3%80%81%E5%A4%9A%E5%85%83%E6%96%87%E5%8C%96%E4%BB%A5%E5%8F%8A%E5%AF%B9%E5%8C%BB%E5%AD%A6%E8%BF%9B%E6%AD%A5%E4%BD%9C%E5%87%BA%E6%98%8E%E7%A1%AE%E8%B4%A1%E7%8C%AE%E6%89%80%E6%BF%80%E5%8A%B1%EF%BC%8C%E2%80%9DQuinot%E8%AF%B4%E3%80%82%E4%BB%96%E6%9C%80%E8%BF%91%E4%B8%8E%E5%88%9D%E5%88%9B%E5%85%AC%E5%8F%B8%E7%9A%84%E5%90%88%E4%BD%9C%E6%98%BE%E7%A4%BA%E4%BA%86%E4%BB%96%E7%9A%84%E5%88%9B%E6%96%B0%E6%84%8F%E6%84%BF%EF%BC%8C%E6%AD%A4%E5%90%8E%E4%BE%BF%E8%A2%ABAOP%20Health%E6%8B%9B%E5%8B%9F%E8%87%B3%E9%AB%98%E5%B1%82%E7%AE%A1%E7%90%86%E5%B2%97%E4%BD%8D%E3%80%82%3C/P%3E%3CP%20%3E%3Ci%20%3E%3Cb%20%3E%E5%85%B3%E4%BA%8E%20AOP%20Health%3C/%20b%20%3E%3C/%20i%20%3E%3C/%20p%20%3E%3C%20p%20%3E%3C%20i%20%3E%20AOP%20Health%20%E6%98%AF%E4%B8%80%E5%AE%B6%E6%80%BB%E9%83%A8%E4%BD%8D%E4%BA%8E%E5%A5%A5%E5%9C%B0%E5%88%A9%E7%9A%84%E5%85%A8%E7%90%83%E6%80%A7%E9%9B%86%E5%9B%A2%EF%BC%8C%E8%87%AA1996%E5%B9%B4%E4%BB%A5%E6%9D%A5%EF%BC%8C%E4%B8%80%E7%9B%B4%E8%87%B4%E5%8A%9B%E4%BA%8E%E5%BC%80%E5%8F%91%E5%88%9B%E6%96%B0%E8%A7%A3%E5%86%B3%E6%96%B9%E6%A1%88%EF%BC%8C%E4%BB%A5%E6%BB%A1%E8%B6%B3%E6%82%A3%E8%80%85%E6%9C%AA%E8%A2%AB%E6%BB%A1%E8%B6%B3%E7%9A%84%E5%8C%BB%E7%96%97%E9%9C%80%E6%B1%82%EF%BC%8C%E5%B0%A4%E5%85%B6%E6%98%AF%E5%9C%A8%E7%A8%80%E6%9C%89%E7%96%BE%E7%97%85%E5%92%8C%E9%87%8D%E7%97%87%E5%8C%BB%E5%AD%A6%E9%A2%86%E5%9F%9F%E3%80%82%E8%AF%A5%E9%9B%86%E5%9B%A2%E5%B7%B2%E6%88%90%E4%B8%BA%E7%BB%BC%E5%90%88%E6%B2%BB%E7%96%97%E8%A7%A3%E5%86%B3%E6%96%B9%E6%A1%88%E9%A2%86%E5%9F%9F%E7%9A%84%E9%87%8D%E8%A6%81%E5%85%88%E9%A9%B1%EF%BC%8C%E5%B9%B6%E9%80%9A%E8%BF%87%E5%AD%90%E5%85%AC%E5%8F%B8%E3%80%81%E4%BB%A3%E8%A1%A8%E5%A4%84%E5%8F%8A%E5%BC%BA%E5%A4%A7%E7%9A%84%E5%90%88%E4%BD%9C%E4%BC%99%E4%BC%B4%E7%BD%91%E7%BB%9C%E7%A7%AF%E6%9E%81%E5%BC%80%E5%B1%95%E5%9B%BD%E9%99%85%E4%B8%9A%E5%8A%A1%E3%80%82%E5%87%AD%E5%80%9F%E2%80%9C%E9%9C%80%E6%B1%82%C2%B7%E7%A7%91%E5%AD%A6%C2%B7%E4%BF%A1%E4%BB%BB%E2%80%9D%E7%9A%84%E5%8F%A3%E5%8F%B7%EF%BC%8CAOP%E5%81%A5%E5%BA%B7%E9%9B%86%E5%9B%A2%E5%BC%BA%E8%B0%83%E5%85%B6%E5%AF%B9%E7%A0%94%E5%8F%91%E6%89%BF%E8%AF%BA%E7%9A%84%E9%87%8D%E8%A6%81%E6%80%A7%EF%BC%8C%E4%BB%A5%E5%8F%8A%E4%B8%8E%E5%8C%BB%E7%94%9F%E5%92%8C%E6%82%A3%E8%80%85%E4%BB%A3%E8%A1%A8%E5%BB%BA%E7%AB%8B%E5%85%B3%E7%B3%BB%EF%BC%8C%E4%BB%A5%E4%BE%BF%E6%9B%B4%E5%A5%BD%E5%9C%B0%E8%80%83%E8%99%91%E8%BF%99%E4%BA%9B%E5%88%A9%E7%9B%8A%E7%9B%B8%E5%85%B3%E8%80%85%E5%9C%A8%E6%95%B4%E4%B8%AA%E4%B8%9A%E5%8A%A1%E8%BF%90%E4%BD%9C%E4%B8%AD%E7%9A%84%E9%9C%80%E6%B1%82%E3%80%82%28aop-health.com%29%3C/i%3E%3C/%20p%20%3E%0A%3CP%20%3E%20%E5%AA%92%E4%BD%93%E8%81%94%E7%B3%BB%EF%BC%9A%3C/%20P%20%3E%0A%3CP%3EAOP%20Orphan%20Pharmaceuticals%20-%20AOP%E5%81%A5%E5%BA%B7%E9%9B%86%E5%9B%A2%E6%88%90%E5%91%98%3Cbr%20/%3EDI%20Isolde%20Fally%3Cbr%20/%3E%E7%94%B5%E8%AF%9D%EF%BC%9A06765004048%3Cbr%20/%3E%E7%94%B5%E5%AD%90%E9%82%AE%E4%BB%B6%EF%BC%9Aisolde.fally%40aop-health.com%3Cbr%20/%3E%E7%BD%91%E7%AB%99%EF%BC%9Ahttps%3A//www.aop-health.com%3C/%20P%20%3E

Im neuen Videopodcast ZIMMER MIT AUSSICHT spricht Moderator und Schauspieler Alexander Mazza mit seinen Gästen über Geschichten, die Kraft geben, ...

%3Cp%3E%3Ci%3EDas%20NULISAseq%E2%84%A2%20CNS%20Disease%20Panel%20120%20und%20das%20Inflammation%20Panel%20250%20f%C3%B6rdern%20die%20Identifizierung%20von%20Biomarkern%20in%2023.000%20L%C3%A4ngsschnittproben%3C/i%3E%3C/p%3E%3Cp%3EAlamar%20Biosciences%2C%20ein%20Unternehmen%2C%20das%20sich%20auf%20pr%C3%A4zise%20Proteomik%20spezialisiert%20hat%20und%20eine%20fr%C3%BChzeitige%20Krankheitsdiagnose%20erm%C3%B6glicht%2C%20hat%20heute%20eine%20strategische%20Partnerschaft%20mit%20dem%20Deutschen%20Zentrum%20f%C3%BCr%20Neurodegenerative%20Erkrankungen%20%28DZNE%29%20bekannt%20gegeben.%20Ziel%20dieser%20Zusammenarbeit%20ist%20der%20Einsatz%20des%20hochsensiblen%20NULISAseq%E2%84%A2%20CNS%20Disease%20Panel%20120%20sowie%20des%20Inflammation%20Panel%20250%20in%20der%20Rheinland-Studie%20%E2%80%93%20einer%20der%20umfassendsten%20und%20innovativsten%20Langzeitstudien%20zur%20Altersforschung%20weltweit%20%E2%80%93%20sowie%20in%20einigen%20spezifischen%20klinischen%20Kohorten%20des%20DZNE.%20Im%20Rahmen%20dieses%20Projekts%20werden%20insgesamt%2023.000%20Plasmaproben%20analysiert%2C%20um%20die%20Entdeckung%20von%20Biomarkern%20zu%20beschleunigen%20und%20das%20Verst%C3%A4ndnis%20f%C3%BCr%20gesundes%20Altern%20sowie%20Neurodegeneration%20zu%20vertiefen.%3C/p%3E%3Cp%3E%E2%80%9EUm%20die%20Mechanismen%20hinter%20Alterung%20und%20Demenz%20zu%20verstehen%2C%20sind%20sowohl%20moderne%20Technologien%20als%20auch%20gut%20definierte%20Kohorten%20erforderlich%22%2C%20erkl%C3%A4rt%20Prof.%20Monique%20Breteler%2C%20Direktorin%20f%C3%BCr%20Bev%C3%B6lkerungs-Gesundheitswissenschaften%20am%20DZNE%20und%20leitende%20Pr%C3%BCferin%20der%20Rheinland-Studie.%20%E2%80%9EDie%20Integration%20von%20Alamar%27s%20Multiplex-Panels%20in%20unsere%20Forschung%20er%C3%B6ffnet%20uns%20neue%20M%C3%B6glichkeiten%20zur%20Entschl%C3%BCsselung%20molekularer%20Signaturen%20im%20Zusammenhang%20mit%20Hirnalterung.%22%3C/p%3E%3Cp%3EDie%20Rheinland-Studie%20des%20DZNE%20ist%20eine%20laufende%20gro%C3%9F%20angelegte%20bev%C3%B6lkerungsbasierte%20Untersuchung%20zur%20Analyse%20der%20Faktoren%20f%C3%BCr%20gesundes%20Altern%20sowie%20die%20Entwicklung%20neurodegenerativer%20Erkrankungen%20%C3%BCber%20den%20gesamten%20Lebenszyklus%20hinweg.%20Mit%20dem%20NULISAseq%20CNS%20Disease%20Panel%20120%20k%C3%B6nnen%20Forscher%20Hunderte%20von%20Gehirn-bezogenen%20Proteinen%20aus%20minimalen%20Blutproben%20mit%20au%C3%9Fergew%C3%B6hnlicher%20Sensitivit%C3%A4t%20messen.%20Besonders%20hervorzuheben%20ist%20die%20F%C3%A4higkeit%20dieses%20Panels%2C%20zwischen%20phosphoryliertem%20Tau%20aus%20dem%20Gehirn%20und%20insgesamt%20phosphoryliertem%20Tau%20im%20Plasma%20zu%20unterscheiden%3B%20dies%20stellt%20einen%20bedeutenden%20Fortschritt%20bei%20der%20fr%C3%BChen%20Erkennung%20neurodegenerativer%20Erkrankungen%20wie%20Alzheimer%20dar.%20Zudem%20bietet%20das%20NULISAseq%20Inflammation%20Panel%20250%20eine%20umfassende%20Analyse%20immunologischer%20Proteine%2C%20die%20an%20Alterungsprozessen%20sowie%20Neuroinflammation%20beteiligt%20sind.%3C/p%3E%3Cp%3EDie%20gewonnenen%20Daten%20zum%20Proteom%20werden%20mit%20den%20umfangreichen%20klinischen%2C%20demografischen%20und%20bildgebenden%20Informationen%20aus%20der%20Studie%20verkn%C3%BCpft%3B%20dies%20erm%C3%B6glicht%20es%20Forschern%2C%20zeitliche%20Ver%C3%A4nderungen%20bei%20Proteinen%20nachzuvollziehen%2C%20fr%C3%BChe%20Biomarker%20zu%20identifizieren%20und%20Entwicklungen%20im%20Bereich%20pr%C3%A4ziser%20Diagnosen%20sowie%20gezielter%20Therapien%20voranzutreiben.%3C/p%3E%3Cp%3E%E2%80%9EDiese%20Kooperation%20stellt%20einen%20bedeutenden%20Fortschritt%20in%20der%20Forschung%20%C3%BCber%20Alterung%20und%20Demenz%20dar%22%2C%20sagt%20Yuling%20Luo%2C%20PhD.%2C%20Gr%C3%BCnderin%20sowie%20CEO%20von%20Alamar%20Biosciences.%20%E2%80%9EDank%20der%20einzigartigen%20Sensitivit%C3%A4t%20unserer%20NULISA-Technologie%20zusammen%20mit%20den%20tiefgreifenden%20Daten%20aus%20der%20DZNE-Rheinland-Studie%20k%C3%B6nnen%20wir%20neuartige%20Protein-Biomarker%20entdecken%20%2Cdie%20Aufschluss%20%C3%BCber%20kognitive%20Gesundheitstrends%20innerhalb%20alternder%20Populationen%20geben.%22%3C/p%3E%3Cp%3EDiese%20Zusammenarbeit%20verdeutlicht%20das%20gemeinsame%20Engagement%20f%C3%BCr%20wissenschaftliche%20Strenge%20ebenso%20wie%20Innovationskraft%20bei%20Forschungsprojekten%20rund%20um%20neurodegenerative%20Krankheiten.%20Durch%20die%20Erfassung%20verschiedener%20Altersverl%C3%A4ufe%20innerhalb%20einer%20detailliert%20charakterisierten%20Bev%C3%B6lkerung%20streben%20Alamar%20Biosciences%20zusammen%20mit%20dem%20DZNE%20danach%20%2Cfr%C3%BChere%20Diagnosen%20%2Cpr%C3%A4zisere%20Prognosen%20sowie%20neue%20therapeutische%20Ans%C3%A4tze%20gegen%20altersbedingte%20Hirnerkrankungen%20voranzubringen.%3C/p%3E%3Cp%3E%3Cb%3EDetaillierte%20Informationen%20zur%20Rheinland-Studie%20des%20DZNE%3C/b%3E%3C/p%3E%3Cp%3EDie%20Rheinland-Studie%20am%20Deutschen%20Zentrum%20f%C3%BCr%20Neurodegenerative%20Erkrankungen%20%28DZNE%29%20verfolgt%20ambitionierte%20Ziele%3A%20Sie%20beobachtet%20Tausende%20Personen%20%C3%BCber%20mehrere%20Jahrzehnte%20hinweg%20%2Cum%20herauszufinden%20%2Cwelche%20Faktoren%20gesundes%20Altern%20beg%C3%BCnstigen%20oder%20neurodegenerative%20Prozesse%20hervorrufen%20k%C3%B6nnen%20.%20Dabei%20werden%20umfangreiche%20klinische%20Daten%20gesammelt%20-%20einschlie%C3%9Flich%20bildgebender%20Verfahren-%2C%20genetischer%20Informationen%20ebenso%20wie%20lifestylebezogener%20Aspekte%20-%20um%20tiefere%20Einblicke%20ins%20alternde%20Gehirn%20gewinnen%20zu%20k%C3%B6nnen%20.%20Weitere%20Infos%20finden%20Sie%20unter%20www.dzne.de/en/%20bzw%20.www.rheinland-studie.de/en/.%3C/P%20%3E%3CP%20%3E%3Cb%20%3E%C3%9Cber%20Alamar%20Biosciences%20Inc.%3C%20/b%20%3E%3C/P%20%3E%3CP%20%3EAlamar%20Biosciences%20ist%20ein%20privates%20Biowissenschaftsunternehmen%20dessen%20Ziel%20es%20ist%20innovative%20L%C3%B6sungen%20im%20Bereich%20Pr%C3%A4zisionsproteomik%20anzubieten%20damit%20Krankheiten%20so%20fr%C3%BChzeitig%20wie%20m%C3%B6glich%20erkannt%20werden%20k%C3%B6nnen%20.%20Die%20firmeneigene%20Plattform%20namens%20NULISA%20kombiniert%20sich%20nahtlos%20mit%20neuesten%20genomischen%20Technologien%20sodass%20Nachweisempfindlichkeiten%20bis%20hinunter%20auf%20den%20Attomolbereich%20erreicht%20werden%20-%20was%20weit%20%C3%BCberlegen%20gegen%C3%BCber%20anderen%20derzeit%20verf%C3%BCgbaren%20Methoden%20zum%20Nachweis%20biologischer%20Marker%20ist%20.%20Mehr%20erfahren%20Sie%20unter%20alamarbio.com.%3C/P%20%3E%3CP%20%3EUrspr%C3%BCnglichen%20Inhalt%20ansehen%3A%20https%3A//www.prnewswire.com/news-releases/alamar-biosciences-und-das-deutsche-zentrum-fur-neurodegenerative-erkrankungen-dzne-arbeiten-an-wegweisender-proteomic-profiling-studie-in-kohorte-der-rheinland-studie-zusammen-302516524.html%3C/%20P%20%3E%3CP%20%3EMedienkontakt%3A%3C/%20P%20%3E%3CP%20%3EApril%20Falcone%2C%3Cbr%20/%3EAlamar%20Biosciences%2C%3Cbr%20/%3E%20afalcone%40alamarbio.com%2C%3Cbr%20/%3E%28510%29838%20-1783%20%3C/%20P%20%3E

Das NULISAseq™ CNS Disease Panel 120 und das Inflammation Panel 250 fördern die Identifizierung von Biomarkern in 23.000 Langzeitproben.Alamar Biosciences, ...

%3Cp%3EEine%20erfahrene%20F%C3%BChrungskraft%20im%20Technologiebereich%20wird%20den%20global%20f%C3%BChrenden%20Anbieter%20von%20L%C3%B6sungen%20zur%20Barrierefreiheit%20in%20die%20n%C3%A4chste%20Phase%20seiner%20kundenorientierten%20Expansion%20leiten.%3C/p%3E%3Cp%3EVispero%C2%AE%2C%20der%20weltweit%20f%C3%BChrende%20Anbieter%20von%20Hilfstechnologien%2C%20hat%20heute%20bekannt%20gegeben%2C%20dass%20Rhonda%20Bassett-Spiers%20mit%20sofortiger%20Wirkung%20als%20neue%20Chief%20Executive%20Officer%20des%20Unternehmens%20eingesetzt%20wurde.%3C/p%3E%3Cp%3ERhonda%20bringt%20%C3%BCber%2025%20Jahre%20Erfahrung%20in%20der%20F%C3%B6rderung%20von%20Unternehmensver%C3%A4nderungen%20und%20Wachstum%20in%20den%20Bereichen%20Technologie%20und%20Software%20zu%20Vispero.%20Zuletzt%20war%20sie%20als%20CEO%20bei%20Telestream%20t%C3%A4tig%2C%20wo%20sie%20erfolgreich%20die%20Produktpalette%20modernisierte%20und%20eine%20neue%20Markteinf%C3%BChrungsstrategie%20entwickelte.%20Davor%20hatte%20sie%20die%20Position%20des%20Pr%C3%A4sidenten%20und%20CEO%20bei%20iTradeNetwork%20inne%2C%20einem%20globalen%20Anbieter%20f%C3%BCr%20Lieferketteninformationen%2C%20wo%20sie%20innovative%20L%C3%B6sungen%20einf%C3%BChrte%20und%20das%20Marktpotenzial%20des%20Unternehmens%20erweiterte.%3C/p%3E%3Cp%3ENeben%20ihren%20F%C3%BChrungsaufgaben%20fungiert%20Rhonda%20auch%20als%20Lead%20Independent%20Director%20bei%20Quorum.%20Dort%20ist%20sie%20verantwortlich%20f%C3%BCr%20die%20Unternehmensf%C3%BChrung%20sowie%20strategische%20Aufsicht%20eines%20Anbieters%20von%20Softwarel%C3%B6sungen%20f%C3%BCr%20%C3%B6ffentliche%20Angelegenheiten.%3C/p%3E%3Cp%3E%E2%80%9EDie%20Mission%20von%20Vispero%20ist%20%C3%A4u%C3%9Ferst%20wichtig%2C%20und%20ich%20f%C3%BChle%20mich%20geehrt%2C%20dieses%20talentierte%20Team%20dabei%20zu%20unterst%C3%BCtzen%2C%20unseren%20Einfluss%20sowie%20unsere%20globale%20Reichweite%20auszubauen%E2%80%9C%2C%20erkl%C3%A4rte%20Rhonda%20Bassett-Spiers%2C%20CEO%20von%20Vispero.%20%E2%80%9EGemeinsam%20werden%20wir%20weiterhin%20innovative%20L%C3%B6sungen%20entwickeln%2C%20um%20blinden%20und%20sehbehinderten%20Menschen%20ein%20Leben%20ohne%20Barrieren%20zu%20erm%C3%B6glichen.%E2%80%9C%3C/p%3E%3Cp%3E%E2%80%9ERhonda%20ist%20eine%20bew%C3%A4hrte%20F%C3%BChrungspers%C3%B6nlichkeit%20mit%20einer%20starken%20Kundenorientierung%20sowie%20einer%20beeindruckenden%20Erfolgsbilanz%E2%80%9C%2C%20erg%C3%A4nzte%20Kevin%20Collins%2C%20Vorsitzender%20des%20Vorstands%20von%20Vispero.%20%E2%80%9EIhre%20strategische%20Vision%20gepaart%20mit%20internationaler%20Erfahrung%20macht%20sie%20zur%20idealen%20Wahl%20f%C3%BCr%20diese%20entscheidende%20Phase%20bei%20Vispero%20%E2%80%93%20einer%20Zeit%20in%20der%20wir%20unsere%20operative%20Exzellenz%20weiter%20verbessern%20wollen.%E2%80%9C%3C/p%3E%3Cp%3EDiese%20Bekanntgabe%20f%C3%A4llt%20zusammen%20mit%20dem%2030-j%C3%A4hrigen%20Jubil%C3%A4um%20von%20Vispero%20sowie%20dem%20legend%C3%A4ren%20Produkt%20JAWS%C2%AE%20%28Job%20Access%20With%20Speech%29%2C%20welches%20das%20meistgenutzte%20Bildschirmleseprogramm%20weltweit%20darstellt.%20Seit%20seiner%20Einf%C3%BChrung%20im%20Jahr%201995%20hat%20JAWS%20revolutioniert%20wie%20blinde%20oder%20sehbehinderte%20Menschen%20auf%20digitale%20Informationen%20zugreifen%20k%C3%B6nnen%20%E2%80%93%20sei%20es%20beim%20Arbeiten%20oder%20beim%20unabh%C3%A4ngigen%20Leben.%20Dieser%20Meilenstein%20verdeutlicht%20das%20anhaltende%20Engagement%20von%20Vispero%20f%C3%BCr%20Innovationen%20im%20Bereich%20Barrierefreiheit%3B%20ein%20Erbe%20welches%20Rhonda%20Bassett-Spiers%20nun%20ins%20n%C3%A4chste%20Kapitel%20f%C3%BChren%20wird.%3C/p%3E%3Cp%3E%C3%9Cber%20Vispero%3C/p%3E%3Cp%3EVispero%C2%AE%20gilt%20als%20der%20weltgr%C3%B6%C3%9Fte%20Anbieter%20an%20Hilfsmittelprodukten%20f%C3%BCr%20Menschen%20mit%20Sehbehinderungen.%20Die%20Marken%20Freedom%20Scientific%2C%20TPGi%2C%20Enhanced%20Vision%20und%20Optelec%20geh%C3%B6ren%20alle%20zu%20Vispero%20und%20blicken%20auf%20eine%20lange%20Geschichte%20innovativer%20Produkte%20zur%C3%BCck%20-%20speziell%20entwickelt%20f%C3%BCr%20Kunden%20mit%20eingeschr%C3%A4nkter%20Mobilit%C3%A4t.%20Unsere%20Produktlinie%20z%C3%A4hlt%20zu%20den%20vielf%C3%A4ltigsten%20und%20zuverl%C3%A4ssigsten%20am%20Markt%3B%20dazu%20geh%C3%B6rt%20auch%20JAWS%20for%20Windows%20%E2%80%93%20die%20f%C3%BChrende%20Software%20zum%20Lesen%20von%20Bildschirmtexten%20weltweit.%20Weitere%20Informationen%20finden%20Sie%20unter%20www.vispera.com.%3C/p%3E%3Ca%20href%3D%22mailto%3AKthomas%40visporo.com%22%3EKthomas%40visporo.com%3C/a%3E%3C/br%3E%0A%3Cp%3EPressekontakt%3A%3C/P%3E%0A%3Cp%3EKody%20Thomas%20%3Cbr%20/%3E%20VP%20Marketing%20%3Cbr%20/%3E%20Kthomas%40visporo.com%3Cbr%20/%3ELogo%20-%20https%3A//mma.prnewswire.com/media/2739520/Visparo_Logo.jpg%3Cbr%20/%3EUrspr%C3%BCnglichen%20Inhalt%20anzeigen%3A%20%3Ca%20href%3D%22https%3A//www.prnewswire.com/news-releases/visparo-ernennt-rhonda-bassett-spiers-zum-ceo-um-innovation-und-wachstum-voranzutreiben-302516507.html%22%3ELink%20zur%20Pressemitteilung%3C/a%3E%3C/P%3E

Eine erfahrene Führungskraft im Technologiebereich wird den führenden Anbieter von Lösungen zur Barrierefreiheit in die nächste Phase seiner kundenorientierten Expansion ...

%3Cp%3E%3Cb%3EDas%20Hamburger%20Biotechnologieunternehmen%20PROVIREX%20Genome%20Editing%20Therapies%20GmbH%20hat%20zusammen%20mit%20dem%20Leibniz-Institut%20f%C3%BCr%20Virologie%20%28LIV%29%2C%20insbesondere%20der%20Arbeitsgruppe%20%22Genomik%20retroviraler%20Erkrankungen%22%20unter%20der%20Leitung%20von%20Dr.%20Dr.%20Ulrike%20Lange%2C%20eine%20F%C3%B6rderung%20in%20H%C3%B6he%20von%201%2C7%20Millionen%20Euro%20erhalten.%20Diese%20Unterst%C3%BCtzung%20stammt%20aus%20dem%20F%C3%B6rderprogramm%20PROFI%20Transfer%20Plus%20der%20Hamburgischen%20Investitions-%20und%20F%C3%B6rderbank%20%28IFB%20Hamburg%29%20sowie%20des%20Europ%C3%A4ischen%20Fonds%20f%C3%BCr%20regionale%20Entwicklung%20%28EFRE%29.%20Das%20gef%C3%B6rderte%20Projekt%20TheraImmun%20zielt%20darauf%20ab%2C%20eine%20modulare%20Gentherapie-Plattform%20zu%20entwickeln%2C%20die%20gezielte%20Modifikationen%20an%20Immunzellen%20erm%C3%B6glicht.%3C/b%3E%3C/p%3E%0A%0A%3Cp%3EDie%20F%C3%B6rderung%20erstreckt%20sich%20%C3%BCber%20einen%20Zeitraum%20von%2030%20Monaten%20ab%20August%202025.%20Die%20erste%20Anwendung%20dieser%20Plattform%20wird%20sich%20auf%20die%20Behandlung%20von%20Infektionen%20mit%20dem%20humanen%20T-lymphotropen%20Virus%201%20%28HTLV-1%29%20konzentrieren%20%E2%80%93%20ein%20Retrovirus%2C%20das%20%C3%A4hnlich%20wie%20HIV%20sein%20virales%20Erbgut%20in%20das%20Erbgut%20der%20Immunzellen%20integriert%20und%20schwerwiegende%20Erkrankungen%20wie%20T-Zell-Leuk%C3%A4mien%20sowie%20neurologische%20St%C3%B6rungen%20hervorrufen%20kann.%3C/p%3E%0A%0A%3Cp%3EBisher%20existieren%20keine%20therapeutischen%20Ans%C3%A4tze%20zur%20Bek%C3%A4mpfung%20von%20HTLV-1%3B%20dies%20soll%20nun%20durch%20das%20gef%C3%B6rderte%20Projekt%20ge%C3%A4ndert%20werden.%20Der%20therapeutische%20Ansatz%20basiert%20auf%20einer%20Designer-Rekombinase%20%28RecHTLV%29%2C%20die%20es%20erm%C3%B6glicht%2C%20das%20in%20den%20Immunzellen%20integrierte%20virale%20Erbgut%20gezielt%20zu%20entfernen.%20Diese%20Rekombinase%20wird%20mithilfe%20viraler%20Transportvehikel%20%28AAV%29%20in%20die%20betroffenen%20Zellen%20eingeschleust%3B%20diese%20Vehikel%20sind%20mit%20spezifischen%20Antik%C3%B6rperfragmenten%20%28VHH-Antik%C3%B6rpern%29%20ausgestattet%2C%20um%20eine%20pr%C3%A4zise%20Adressierung%20zu%20gew%C3%A4hrleisten.%3C/p%3E%0A%0A%3Cp%3EDie%20Technologie%20beruht%20auf%20einer%20bereits%20patentierten%20L%C3%B6sung%20zur%20Entfernung%20integrierter%20HIV-DNA%2C%20die%20zuvor%20von%20PROVIREX%20entwickelt%20wurde.%20Im%20Rahmen%20des%20Projekts%20TheraImmun%20wird%20diese%20Technologie%20kombiniert%20mit%20der%20Expertise%20bez%C3%BCglich%20VHH-Antik%C3%B6rper-AAV-Transportvehikel%20am%20LIV%20eingesetzt.%20Dar%C3%BCber%20hinaus%20kommen%20w%C3%A4hrend%20des%20Projekts%20auch%203D-Organoidmodelle%20zum%20Einsatz%3B%20diese%20realit%C3%A4tsnahen%20Gewebemodelle%20erm%C3%B6glichen%20pr%C3%A4zisere%20und%20ethisch%20vertretbare%20Forschung%20ohne%20Tierversuche.%3C/p%3E%0A%0A%3Cp%3EDr.%20Niklas%20Beschorner%2C%20Forschungsleiter%20bei%20PROVIREX%2C%20hebt%20hervor%3A%20%3Ci%3E%22Diese%20Partnerschaft%20vereint%20unsere%20fortschrittliche%20Plattformtechnologie%20mit%20herausragender%20virologischer%20Forschung%20und%20legt%20gemeinsam%20mit%20dem%20LIV%20den%20Grundstein%20f%C3%BCr%20zielgerichtete%20Gentherapien%20gegen%20HTLV-1.%22%3C/i%3E%3C/p%3E%0A%0A%3Cp%3EDr.%20Dr.%20Ulrike%20Lange%20erg%C3%A4nzt%20als%20Leiterin%20der%20Forschungsgruppe%20%22Genomik%20Retroviraler%20Infektionen%22%20am%20LIV%3A%20%3Ci%3E%22HTLV-1%20stellt%20oft%20eine%20untersch%C3%A4tzte%20globale%20Gesundheitsbedrohung%20dar%3B%20durch%20unsere%20Zusammenarbeit%20mit%20PROVIREX%20k%C3%B6nnen%20wir%20wissenschaftliche%20Erkenntnisse%20direkt%20in%20innovative%20Therapieans%C3%A4tze%20umsetzen.%22%3C/i%3E%3C/p%3E%0A%0A%3Cp%3EDr.%20Carsten%20Lohmann%20vom%20IFB%20Hamburg%20%C3%A4u%C3%9Fert%3A%20%3Ci%3E%22Wir%20w%C3%BCnschen%20den%20Partnern%20im%20Projekt%20viel%20Erfolg%20bei%20diesem%20technologisch%20anspruchsvollen%20%27Leuchtturm-Projekt%27%20und%20freuen%20uns%20dar%C3%BCber%20hinaus%20%C3%BCber%20unseren%20Beitrag%20zur%20Weiterentwicklung%20des%20Life%20Science%20Standorts%20Hamburg.%22%3C/i%3E%3C/p%3E%0A%0A%3Cp%3EDieses%20Projekt%20ist%20ein%20Beispiel%20daf%C3%BCr%2C%20wie%20das%20Programm%20PROFI%20Transfer%20Plus%20Forschungskooperationen%20f%C3%B6rdert%20%E2%80%93%20um%20zentrale%20Herausforderungen%20im%20Bereich%20Gesundheit%20und%20Biotechnologie%20anzugehen%20-%20sowohl%20regional%20als%20auch%20international%20relevant.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3E%C3%9Cber%20die%20PROVIREX%20Genome%20Editing%20Therapies%20GmbH%3C/b%3E%3C/p%3E%0A%3Cp%3EDIE%20Firma%20PROVIREX%20Genome%20Editing%20Therapies%20GmbH%20aus%20Hamburg%20ist%20ein%20privates%20Biotech-Unternehmen%20spezialisiert%20auf%20Arzneimittelentwicklung%20f%C3%BCr%20neuartige%20Therapien%20%28ATMPs%29.%20Mit%20ihrer%20propriet%C3%A4ren%20Genomeditierungstechnologie%20zielt%20sie%20darauf%20ab%20integrierte%20virale%20DNA%20pr%C3%A4zise%20aus%20infizierten%20Zellen%20zu%20eliminieren%20und%20damit%20lebensbedrohliche%20Virusinfektionen%20zu%20heilen%20%E2%80%93%20insbesondere%20bei%20HIV-infizierten%20Patienten%20unter%20Verwendung%20hochspezifischer%20Designer-Rekombinasen%20als%20Kerntechnologie.%3Cbr%20/%3EPROVIREX%20wurde%20im%20Oktober%202019%20gegr%C3%BCndet%20und%20erhielt%20bereits%20im%20Jahr%202020%20Startfinanzierungen.%3Cbr%20/%3ESeit%20Juli%202022%20z%C3%A4hlen%20BIOVENTURE%20Consulting%20GmbH%20sowie%20die%20Freie%20Hansestadt%20Hamburg%20%C3%BCber%20IFB%20zu%20ihren%20Investoren.%3Cbr%20/%3EMit%20exklusiven%20Technologielizenzen%20arbeitet%20ein%20engagiertes%20Team%20daran%20zuk%C3%BCnftige%20Entwicklungen%20im%20Bereich%20Genomeditierungs-Therapien%20voranzubringen.%3Cbr%20/%3EWeitere%20Informationen%20finden%20Sie%20unter%20www.provirex.de.%3C/p%3E%0A%20%20%0A%3Cp%3E%3Cb%3E%C3%9Cber%20das%20Leibniz-Institut%20f%C3%BCr%20Virologie%3C/b%3E%3C/p%3E%0A%3CP%3EAn%20diesem%20Institut%20werden%20humanpathogene%20Viren%20erforscht%3B%20Ziel%20ist%20es%20virusbedingte%20Infektionskrankheiten%20besser%20zu%20verstehen%20sowie%20neue%20Therapieans%C3%A4tze%20auszuw%C3%A4hlen.%3Cbr%20/%3EAuf%20Basis%20experimenteller%20Grundlagenforschung%20entstehen%20neue%20Strategien%20zur%20Behandlung%20bedeutender%20viral%20bedingter%20Infektionserreger%20weltweit.%3Cbr%20/%3EDas%20LIV%20agiert%20als%20gemeinn%C3%BCtzige%20Forschungseinrichtung%20seit%20seiner%20Gr%C3%BCndung1995%20innerhalb%20der%20Leibniz-Gemeinschaft%2C%3Cbr/%3Efinanziert%20teilweise%20durch%20Bundesministerium%20f%C3%BCr%20Gesundheit%20%26%20gemeinsamer%20Forschungsf%C3%B6rderung%3Cbr/%3Eder%20L%C3%A4nder%20vertreten%20durch%20Beh%C3%B6rde%20Wissenschaft%2CForschung%2CGleichstellung%28BWFG%29%3Cbr/%3EHamburg.Das%20Team%20%22Genomik%20Retroviraler%20Infektionen%22%2C%20geleitet%20von%20Dr.Dr.Ulrike%20Lange%2Cforscht%20seit%20ihrer%20Integration%20ins%20LIV%282022%29%2Cwie%20HIV%20trotz%20bestehender%20Therapie%20weiterhin%20immunologische%20Hemmungen%20verursacht.Fokus%20liegt%20zudem%20auf%20endogenen%20Retroviren%2Cdiese%20wurden%20evolution%C3%A4r%20erworben%26pr%C3%A4gen%20Funktion%20unseres%20Immunsystems.Das%20BMBF%20finanziert%20prim%C3%A4r%20dieses%20Team.F%C3%BCr%20weitere%20Informationen%20besuchen%20Sie%20bitte%20www.leibniz-liv.de%3C/P%3E%0A%20%20%0A%3CP%3E%3Cb%3EKurzinfo%20zur%20IFB-Hamburg%3C/b%3E%3C/P%3E%0A%3CP%3EDIE%20hamburgische%20Investitions-%26F%C3%B6rderbank%20gilt%20als%20zentrale%20Anlaufstelle%20bez%C3%BCglich%20F%C3%B6rderm%C3%B6glichkeiten%20privatpersonen/Unternehmen/institutionelle%20Einrichtungen%3Cbr/%3EHamburgs.Sie%20bietet%20Beratung%20hinsichtlich%20s%C3%A4mtlicher%20Angebote%20Stadt/Bund/EUunterst%C3%BCtzt.Hamburger%20Struktur-%2CWirtschaftspolitiken%2C%26soziale%20Anliegen.Zus%C3%A4tzlich%20erf%C3%BCllt%20sie%20%C3%B6ffentliche%20Aufgaben.Von%20Wohnraumf%C3%B6rderung%20bis%20hin%20Innovationsf%C3%B6rderungsma%C3%9Fnahmen%20reicht%20ihr%20Aufgabenspektrum.Wenn%20Unternehmen%20innovativ%20sind%2Ck%C3%B6nnen%20sie%20sogar%20Beteiligungsm%C3%B6glichkeiten%20nutzen.Unterst%C3%BCtzung%20erfolgt%20mittels%20Zusch%C3%BCssen%2CDarlehen%20oder%20B%C3%BCrgschaften.F%C3%BCr%20mehr%20Infos%20siehe%3Awww.ifbhh.de%20%3C/P%3E%0A%20%20%0A%3CP%3E%3Cb%3EZukunftsaussichten%3A%3C/b%3E%3C/P%3E%0A%3CP%3EDIE%20Pressemitteilung%20enth%C3%A4lt%20Annahmen/Erwartungen/prognosen%20betreffend%20k%C3%BCnftiger%20Entwicklungen%20Branche/rechtlichen/wirtschaftlichen%20Rahmenbedingungen%20ProviRex.Gmbh.S%C3%A4mtliche%20Annahmen/Erwartungen/prognosen%20sind%20unsicher%20%26unterliegen%20jederzeit%20Risiken%28insbesondere%20%C3%BCblich%20Risikos%20biopharmazeutischer%20Unternehmen%29%3AProdukt-/Rohstoffpreise%2CEffekte%20Arzneimittelsicherheit%2CW%C3%A4hrungsrisiken%2CBestimmungen%20staatlicher%20Vorschriften%2C%26politische%20Instabilit%C3%A4t.Tats%C3%A4chliches%20Ereignisse/k%C3%BCnftige%20Entwicklungen%20k%C3%B6nnen%20erheblich%20variieren%20gegen%C3%BCber%20hier%20skizzierten%20Erwartungen.Investor%20tr%C3%A4gt%20keinerlei%20Verantwortung%20Aktualisierung%20solcher%20Aussagen%20bzgl.k%C3%BCnftiger%20Branchenentwicklungen%20oder%20Unternehmensverh%C3%A4ltnisse%21%3C/P%3E%0A%20%0A%3CP%3EPressekontakt%3A%3C/P%3E%3CP%20%3EPROVI%20REX%20Kontakt%3A%3CBR/%3EDr.NIKLAS%20BESCHORNEN%2C%3CBR/%3E%3Cstrong%20%3EPROVI%20REX%20GENOME%20EDITING%20THERAPIES%20GMBH%2C%3CBR/%3E%3C/strong%20%3E22547%20HAMBURG%2CTEL.%3A%2B49%280%2940%E2%80%93999969190%2C%3CBR/%3E%3CEMAIL%3E%3Aniklas.beschorner%40provirex.de%3CBR/%3E%3CBr%20/%3E%3C/%20P%20%3E%0A%20%0A%3CP%3ELIV%20KONTAKT%3A%3CBr%20/%3E%3Cstrong%20%3EDR.DR.UlRIKE%20LANGE%2C%3CBR/%3E%3C/strong%20%3E%3CEMPHASIS%20%3ELEIBNIZ-INSTITUT%20F%C3%9CR%20VIROLOGIE%3CBr%20/%3E%3C/EMPHASIS%20%3E%3CSTRONG%3E%2C20251%20HAMBURG%3CTEL%3E%3A%20%2B49%280%20%2940%E2%80%9348051261%20%2CEMAIL%20%3Aulrike.lange%40leibniz-liv.de%3C%20BR%20/%3E%3C%20Br%20/%3E%3C/%20P%20%3E%0A%20%0A%20%3C%20P%3EPRESSEKONTAKT%3A%3CSTRONG%3Ewiebke%20fern%20bacher%3Cbr%20/%3E%3C/%20STRONG%20%3E%28%20brickenkamp-pr%20gmbh%29%3CSTRONG%3E%2C47798%20KREFELD%2CTEL.%3A%2B49%280%20%2921516214600%20%2CEMAIL%20%3Afern%20bacher%40%20brickenkamp%20.de%20%3C/%20P%20%3E%0A

%3Cp%3E%E5%9C%A8%E6%9F%8F%E6%9E%97%E5%92%8C%E6%B3%95%E5%85%B0%E5%85%8B%E7%A6%8F%E4%B8%BE%E8%A1%8C%E7%9A%84%E4%B8%A4%E5%9C%BA%E7%8B%AC%E5%AE%B6Apotalk%E6%B4%BB%E5%8A%A8%E4%B8%AD%EF%BC%8CKlose%20Consulting%20GmbH%E4%BD%9C%E4%B8%BA%E4%B8%BB%E8%A6%81%E8%B5%9E%E5%8A%A9%E5%95%86%EF%BC%8C%E5%90%B8%E5%BC%95%E4%BA%86%E8%B6%85%E8%BF%87180%E5%90%8D%E5%8F%82%E4%B8%8E%E8%80%85%EF%BC%8C%E4%B8%BA%E8%8D%AF%E5%BA%97%E7%9A%84%E6%9C%AA%E6%9D%A5%E5%8F%91%E5%B1%95%E6%B3%A8%E5%85%A5%E4%BA%86%E9%87%8D%E8%A6%81%E5%8A%A8%E5%8A%9B%E3%80%82%E8%BF%99%E5%AE%B6%E4%B8%93%E6%B3%A8%E4%BA%8E%E6%95%B0%E5%AD%97%E8%8D%AF%E5%BA%97%E8%90%A5%E9%94%80%E7%9A%84%E5%92%A8%E8%AF%A2%E5%85%AC%E5%8F%B8%E4%B8%8D%E4%BB%85%E6%98%AF%E8%BF%99%E4%B8%A4%E5%9C%BA%E6%B4%BB%E5%8A%A8%E7%9A%84%E5%90%88%E4%BD%9C%E4%BC%99%E4%BC%B4%EF%BC%8C%E8%BF%98%E7%A7%AF%E6%9E%81%E5%8F%82%E4%B8%8E%E5%86%85%E5%AE%B9%E5%88%9B%E4%BD%9C%EF%BC%8C%E6%8F%90%E4%BE%9B%E5%85%B7%E4%BD%93%E7%AD%96%E7%95%A5%E3%80%81%E6%98%8E%E7%A1%AE%E7%9A%84%E4%BF%A1%E6%81%AF%E4%BB%A5%E5%8F%8A%E5%AF%B9%E8%8D%AF%E5%BA%97%E6%97%A5%E5%B8%B8%E7%BB%8F%E8%90%A5%E6%8C%91%E6%88%98%E7%9A%84%E5%AE%9E%E7%94%A8%E8%A7%81%E8%A7%A3%E3%80%82%3C/p%3E%0A%0A%3Cp%3E%3Cb%3E%E8%81%9A%E7%84%A6%E6%88%98%E7%95%A5%E6%80%A7%E8%8D%AF%E5%BA%97%E8%90%A5%E9%94%80%E4%B8%8E%E5%8F%AF%E8%A1%A1%E9%87%8F%E7%9A%84%E7%A4%BE%E4%BA%A4%E5%AA%92%E4%BD%93%E6%88%90%E5%B0%B1%3C/b%3E%3C/p%3E%0A%0A%3Cp%3E%E5%9C%A83%E6%9C%8819%E6%97%A5%E4%BA%8E%E6%9F%8F%E6%9E%97%E5%92%8C6%E6%9C%8811%E6%97%A5%E5%9C%A8%E6%B3%95%E5%85%B0%E5%85%8B%E7%A6%8F%E4%B8%BE%E5%8A%9E%E7%9A%84Apotalks%E4%B8%8A%EF%BC%8CKlose%20Consulting%20GmbH%E7%9A%84%E9%A6%96%E5%B8%AD%E6%89%A7%E8%A1%8C%E5%AE%98%E5%B0%BC%E5%8F%A4%E6%8B%89%E6%96%AF%C2%B7%E5%85%8B%E6%B4%9B%E6%96%AF%EF%BC%88Nicolas%20Klose%EF%BC%89%E5%88%86%E5%88%AB%E8%BF%9B%E8%A1%8C%E4%BA%86%E4%B8%BB%E9%A2%98%E6%BC%94%E8%AE%B2%EF%BC%9A%3C/p%3E%0A%0A%3Cp%3E%E5%9C%A8%E6%9F%8F%E6%9E%97%EF%BC%8C%E4%BB%96%E6%8E%A2%E8%AE%A8%E4%BA%86%E2%80%9C%E4%BB%8E%E5%AE%A2%E6%88%B7%E8%A7%86%E8%A7%92%E7%9C%8B%E8%8D%AF%E5%BA%97%E8%90%A5%E9%94%80%E2%80%9D%E7%9A%84%E4%B8%BB%E9%A2%98%EF%BC%9A%3C/p%3E%0A%0A%3Cp%3E%3Ci%3E%E2%80%9C%E8%AE%B8%E5%A4%9A%E8%8D%AF%E6%88%BF%E8%80%81%E6%9D%BF%E9%9A%BE%E4%BB%A5%E7%AB%99%E5%9C%A8%E5%AE%A2%E6%88%B7%E7%AB%8B%E5%9C%BA%E6%80%9D%E8%80%83%E3%80%82%E7%84%B6%E8%80%8C%EF%BC%8C%E8%BF%99%E6%AD%A3%E6%98%AF%E5%B0%86%E6%95%B0%E5%AD%97%E5%8C%96%E6%8E%AA%E6%96%BD%E6%AD%A3%E7%A1%AE%E5%AE%9A%E4%BD%8D%E4%BA%8E%E5%85%B7%E4%BD%93%E9%9C%80%E6%B1%82%E3%80%81%E6%83%85%E6%84%9F%E5%92%8C%E6%9C%9F%E6%9C%9B%E4%B8%AD%E7%9A%84%E5%85%B3%E9%94%AE%E3%80%82%E2%80%9D%3C/i%3E%3C/p%3E%0A%0A%3Cp%3E%E8%80%8C%E5%9C%A8%E6%B3%95%E5%85%B0%E5%85%8B%E7%A6%8F%EF%BC%8C%E4%BB%96%E5%88%99%E5%85%B3%E6%B3%A8%E7%A4%BE%E4%BA%A4%E5%AA%92%E4%BD%93%EF%BC%8C%E5%B9%B6%E5%8F%91%E8%A1%A8%E9%A2%98%E4%B8%BA%E2%80%9C%E5%8F%AF%E8%A1%A1%E9%87%8F%E6%88%90%E5%8A%9F%EF%BC%8C%E8%80%8C%E9%9D%9E%E7%9B%B2%E7%9B%AE%E5%B0%9D%E8%AF%95%E7%A4%BE%E4%BA%A4%E5%AA%92%E4%BD%93%E2%80%9D%E7%9A%84%E6%BC%94%E8%AE%B2%EF%BC%9A%3C/p%3E%0A%0A%3Cp%3E%3Ci%3E%E2%80%9C%E5%BE%88%E5%A4%9A%E8%8D%AF%E6%88%BF%E5%AF%B9%E5%85%B6%E7%A4%BE%E4%BA%A4%E5%AA%92%E4%BD%93%E8%A1%A8%E7%8E%B0%E5%B9%B6%E4%B8%8D%E9%87%8D%E8%A7%86%EF%BC%8C%E4%BD%86%E9%80%9A%E8%BF%87%E6%AD%A3%E7%A1%AE%E7%AD%96%E7%95%A5%EF%BC%8C%E6%AF%8F%E6%9C%88%E5%8F%AF%E4%BB%A5%E5%AE%9E%E7%8E%B0%E4%BA%94%E4%BD%8D%E6%95%B0%E6%94%B6%E5%85%A5%E2%80%94%E2%80%94%E8%BF%99%E4%B8%80%E5%88%87%E9%83%BD%E6%98%AF%E5%8F%AF%E6%B5%8B%E9%87%8F%E3%80%81%E5%8F%AF%E8%BF%BD%E6%BA%AF%E4%B8%94%E5%85%B7%E5%A4%87%E6%89%A9%E5%B1%95%E6%80%A7%E7%9A%84%E3%80%82%E2%80%9D%3C/i%3E%3C/p%3E%0A%0A%3Cp%3E%E4%BB%96%E7%9A%84%E6%A0%B8%E5%BF%83%E8%A7%82%E7%82%B9%E6%98%AF%EF%BC%9A%E6%95%B0%E5%AD%97%E5%8C%96%E8%83%BD%E8%A7%81%E5%BA%A6%E4%B8%8D%E6%98%AF%E9%99%84%E5%8A%A0%E9%80%89%E9%A1%B9%EF%BC%8C%E8%80%8C%E6%98%AF%E5%95%86%E4%B8%9A%E6%88%90%E5%8A%9F%E7%9A%84%E9%87%8D%E8%A6%81%E5%89%8D%E6%8F%90%E2%80%94%E2%80%94%E5%B0%A4%E5%85%B6%E6%98%AF%E5%9C%A8%E5%BD%93%E5%89%8D%E4%B8%93%E4%B8%9A%E4%BA%BA%E6%89%8D%E7%9F%AD%E7%BC%BA%E3%80%81%E7%AB%9E%E4%BA%89%E5%8A%A0%E5%89%A7%E5%8F%8A%E7%BB%8F%E6%B5%8E%E5%8E%8B%E5%8A%9B%E5%A2%9E%E5%A4%A7%E7%9A%84%E8%83%8C%E6%99%AF%E4%B8%8B%E3%80%82%3C/p%3E%0A%0A%3Cp%3E%3Cb%3EKlose%20Consulting%20%E2%80%93%20%E8%8D%AF%E5%93%81%E5%B8%82%E5%9C%BA%E6%95%B0%E5%AD%97%E8%BD%AC%E5%9E%8B%E4%B9%8B%E4%BC%B4%E4%BE%A3%3C/b%3E%3C/p%3E%0A%0A%3Cp%3EKlose%20Consulting%20GmbH%E6%98%AF%E4%B8%80%E5%AE%B6%E9%A2%86%E5%85%88%E4%BA%8EDACH%E5%9C%B0%E5%8C%BA%EF%BC%88%E5%BE%B7%E5%9B%BD%E3%80%81%E5%A5%A5%E5%9C%B0%E5%88%A9%E5%92%8C%E7%91%9E%E5%A3%AB%EF%BC%89%E7%9A%84%E6%95%B0%E5%AD%97%E5%8C%96%E5%92%A8%E8%AF%A2%E6%9C%BA%E6%9E%84%EF%BC%8C%E4%B8%93%E6%B3%A8%E4%BA%8E%E5%B8%AE%E5%8A%A9%E8%8D%AF%E6%88%BF%E6%8F%90%E5%8D%87%E7%9F%A5%E5%90%8D%E5%BA%A6%E3%80%81%E6%8B%9B%E5%8B%9F%E5%90%88%E6%A0%BC%E4%BA%BA%E6%89%8D%E5%B9%B6%E5%A2%9E%E5%BC%BA%E7%BB%8F%E6%B5%8E%E6%95%88%E7%9B%8A%E3%80%82%3C/p%3E%0A%0A%3Cp%3E%3Ci%3E%22%E6%88%91%E4%BB%AC%E7%9A%84%E7%9B%AE%E6%A0%87%E6%98%AF%E8%AE%A9%E6%AF%8F%E4%B8%AA%E8%8D%AF%E6%88%BF%E9%83%BD%E4%B8%BA%E6%9C%AA%E6%9D%A5%E5%81%9A%E5%A5%BD%E5%87%86%E5%A4%87%E2%80%94%E2%80%94%E6%97%A0%E8%AE%BA%E6%98%AF%E5%9C%A8%E5%95%86%E4%B8%9A%E8%BF%90%E8%90%A5%E4%B8%8A%E8%BF%98%E6%98%AF%E9%A2%86%E5%AF%BC%E5%8A%9B%E6%96%B9%E9%9D%A2%EF%BC%8C%E2%80%9D%3C/i%3E%20%E5%85%8B%E6%B4%9B%E6%96%AF%E8%A1%A8%E7%A4%BA%E3%80%82%3Ci%3E%22%E8%BF%99%E9%9C%80%E8%A6%81%E6%B8%85%E6%99%B0%E6%B5%81%E7%A8%8B%E3%80%81%E6%9C%89%E5%8A%9B%E5%9C%A8%E7%BA%BF%E5%BD%A2%E8%B1%A1%E4%BB%A5%E5%8F%8A%E5%BB%BA%E7%AB%8B%E4%BF%A1%E4%BB%BB%E6%84%9F%E7%9A%84%E5%93%81%E7%89%8C%E6%88%98%E7%95%A5%EF%BC%8C%E6%97%A0%E8%AE%BA%E5%AF%B9%E4%BA%8E%E5%AE%A2%E6%88%B7%E8%BF%98%E6%98%AF%E6%96%B0%E5%91%98%E5%B7%A5%E8%80%8C%E8%A8%80%E3%80%82%E2%80%9D%3C/i%3E%3C/p%3E%0A%0A%3Cp%3EKlose%20Consulting%E5%87%AD%E5%80%9F%E5%8D%81%E4%BD%99%E5%B9%B4%E7%9A%84%E5%9C%A8%E7%BA%BF%E8%90%A5%E9%94%80%E7%BB%8F%E9%AA%8C%EF%BC%8C%E4%B8%BA%E7%8B%AC%E7%AB%8B%E7%BB%8F%E8%90%A5%E6%A8%A1%E5%BC%8F%E4%B8%8B%E7%9A%84%E8%8D%AF%E6%88%BF%E5%B8%A6%E6%9D%A5%E4%BA%86%E4%B8%B0%E5%AF%8C%E7%9F%A5%E8%AF%86%E4%B8%8E%E6%B7%B1%E5%88%BB%E7%90%86%E8%A7%A3%E3%80%82%3C/p%3E%0A%0A%3Cp%3E%3Cb%3EApotalk%202025%EF%BC%9A%E4%BA%A4%E6%B5%81%E3%80%81%E5%90%AF%E5%8F%91%E4%B8%8E%E5%AE%9E%E9%99%85%E8%A7%A3%E5%86%B3%E6%96%B9%E6%A1%88%3C/b%3E%3C/p%3E%0A%20%0A%20%3Cul%3E%0A%3Cli%3E%20%E8%8D%AF%E5%BA%97%E6%97%A5%E5%B8%B8%E4%B8%AD%E7%9A%84%E4%BA%BA%E5%B7%A5%E6%99%BA%E8%83%BD%20%3C/li%3E%0A%3Cli%3E%20%E6%95%B0%E5%AD%97%E5%8C%96%E5%91%98%E5%B7%A5%E6%8B%9B%E8%81%98%20%3C/li%3E%0A%3Cli%3E%20%E4%BB%8E%E5%AE%A2%E6%88%B7%E8%A7%92%E5%BA%A6%E7%9C%8B%E7%A4%BE%E4%BA%A4%E5%AA%92%E4%BD%93%20%3C/li%3E%0A%3Cli%3E%20%E5%81%A5%E5%BA%B7%E8%A1%8C%E4%B8%9A%E4%B8%AD%E7%9A%84%E5%BD%B1%E5%93%8D%E8%80%85%E8%90%A5%E9%94%80%20%3C/li%3E%0A%3Cli%20%3E%20%E6%9C%AA%E6%9D%A5%E5%93%81%E7%89%8C%E5%BB%BA%E8%AE%BE%E4%B8%AD%E7%9A%84%E8%97%A5%E5%B1%80%20%3C/li%3E%0A%20%3C/ul%3E%0A%0A%0A%20%3CP%3EThe%20central%20idea%20was%20to%20provide%20insights%2C%20shift%20perspectives%2C%20and%20showcase%20practical%20strategies%20that%20can%20be%20directly%20implemented%20in%20daily%20pharmacy%20operations.%3C/P%3E%0A%0A%0A%20%3CP%20%3E%3CB%20%3E%E5%B1%95%E6%9C%9B%EF%BC%9A2025%E5%B9%B4%E6%95%B0%E5%AD%97%E5%8C%96%E5%8C%BB%E5%8A%A1%E4%BA%BA%E5%91%98%E6%97%A5%20-%20%E4%B8%8B%E4%B8%80%E6%AD%A5%E5%8F%91%E5%B1%95%E6%96%B9%E5%90%91%0A%20%20%20%20The%20strong%20response%20to%20the%20Apotalks%20was%20a%20clear%20signal%20for%20Klose%20Consulting%3A%20there%20is%20an%20enormous%20demand%20for%20in-depth%20consulting%2C%20inspiration%2C%20and%20exchange.%0A%20%20%20%20In%20response%2C%20Klose%20Consulting%20GmbH%20will%20launch%20its%20own%20event%20format%20called%20%22Pharmacy%20Digital%20Day%22%20in%20the%20fall%20of%202025.%0A%20%20%20%20%22With%20Pharmacy%20Digital%20Day%2C%20we%20are%20creating%20a%20platform%20for%20pharmacy%20owners%20who%20want%20to%20make%20real%20progress.%20We%20will%20discuss%20what%20many%20pharmacies%20urgently%20need%20but%20rarely%20receive%3A%20measurable%20results%2C%20strategic%20clarity%2C%20and%20real%20solutions%2C%22%20explains%20Klose.%3C/B%20%3E%3C/P%20%3E%0A%0A%3CP%3EThe%20focus%20will%20include%3A%3C/P%20%3E%0A%3Cul%20%3E%0A%3Cli%20%3E%20%E7%A4%BE%E4%BC%9A%E6%8B%9B%E8%81%98%E7%9A%84%E6%96%B0%E6%96%B9%E6%B3%95%0A%20%20%20%20%20%20%20%20Li%20%3E%3CLi%20%3E%20%E5%8F%AF%E6%B5%8B%E9%87%8F%E7%A4%BE%E4%BC%9A%E5%AA%92%E4%BB%8B%E7%AD%96%E7%95%A5%0A%20%20%20%20%20%20%20%20Li%20%3E%3CLi%20%3E%20%E6%8F%90%E5%8D%87%E8%97%A5%E5%B1%80%E6%95%B8%E4%BD%8D%E8%83%BD%E8%A6%8B%E5%BA%A6%0A%20%20%20%20%20%20%20%20Li%20%3E%3CLi%20%3E%20%E8%87%AA%E5%8A%A8%E5%8C%96%E5%8F%8A%E6%B5%81%E7%A8%8B%E4%BC%98%E5%8C%96%0A%20%20%20%20%20%20%20%20Li%20%3E%3CLi%20%3E%20%E5%9C%A8%E5%8C%BA%E5%9F%9F%E7%AB%9E%E4%BA%89%E4%B8%AD%E5%A1%91%E9%80%A0%E5%BC%BA%E5%A4%A7%E5%93%81%E7%89%8C%E5%BD%A2%E8%B1%A1%0A%20%20%20%20%20%20%20li%20%3E%3C/UL%20%3E%0A%0A%3CP%3E%22%E6%88%91%E4%BB%AC%E6%AD%A3%E5%9C%A8%E6%8E%A8%E5%8A%A8%E5%8C%BB%E5%8A%A1%E7%95%8C%E5%8F%98%E9%9D%A9%EF%BC%8C%E5%9B%A0%E4%B8%BA%E6%88%91%E4%BB%AC%E5%B8%8C%E6%9C%9B%E6%94%B9%E5%8F%98%E5%81%A5%E5%BA%B7%E4%BA%A7%E4%B8%9A%E3%80%82%22%20%0A%20%20%20Details%20and%20dates%20regarding%20the%20Pharmacy%20Digital%20Day%20will%20be%20published%20shortly%20at%20www.kloseconsulting.de.%20%0A%20%20%20%3CB%20style%3D%22font-weight%3Abold%3B%22%3E%E6%9B%B4%E5%A4%9A%E4%BF%A1%E6%81%AF%EF%BC%9A%0A%20%20%20KLOSE%20CONSULTING%20GMBH%20DIGITAL%20STRATEGIES%20FOR%20PHARMACIES%20AND%20HEALTH%20BUSINESSES%20www.kLOSECONSULTING.DE%20WWW.NICOLASKLOSE.DE%20APOTALK%20INFO%3A%20WWW.APO-TALK.DE%20PRESS%20CONTACT%3A%0A%20%20%20kLOSE%20CONSULTING%20GMBH%20NICOLAS%20kLOSE%20E-MAIL%3A%20KONTAKT%40kLOSeConsulting.de%20WEBSITE%3A%20HTTPS%3A//kLOSeConsulting.de/%20PRESS%20CONTACT%3A%0A%20%20%20RUBEN%20SCH%C3%84FER%20E-MAIL%3A%20REDAKTION%40DCFVERLAG.DE%22%3C/B%20%3E%3C/P%20%3E%0A

在柏林和法兰克福举行的两场独家Apotalk活动中，Klose Consulting GmbH作为主要赞助商，吸引了超过180名参与者，为药店的未来发展注入了重要动力。这家专注于数字药店营销的咨询公司不仅是这两场活动的合作伙伴，还积极参与内容设计，提供切实可行的策略、明确的信息，以及对药店日常经营挑战的实际洞察。 聚焦战略性药店营销与可量化社交媒体成就 在3月19日于柏林和6月11日在法兰克福举办的Apotalks上，Klose Consulting GmbH的首席执行官尼古拉斯·克洛斯（Nicolas Klose）分别进行了主题演讲： 在柏林，他探讨了“从客户视角看药店营销”的话题： “许多药房老板难以站在客户立场思考。然而，这正是将数字措施有效对接到具体需求、情感和期望中的关键。” 而在法兰克福，他则将目光投向社交媒体，发表题为“可测量成功，而非盲目追求社交媒体”的演讲： “很多药房对其社交媒体形象并不重视，但通过正确策略，每月可以实现五位数收入——这一切都是可以衡量、追踪及扩展的。” 他的核心信息是：提升数字能见度不是一种选择，而是商业成功的重要前提——尤其是在专业人才短缺、竞争加剧以及经济压力增大的当下。 Klose Consulting – 药品市场数字转型之伴侣 Klose Consulting GmbH是一家领先于DACH地区（德国、奥地利和瑞士）的数字咨询机构，专注于帮助药房进行员工招聘及社交媒体营销。该公司致力于协助药房老板提高知名度，引进合格人才，并使其业务更加成功。 ...